cedric francois

👨🏽‍🎤

[cedric francois @cgfran01]

@steen1969 @ApellisPharma Haha! Missing Louavul 🥰

[Apellis Pharma @ApellisPharma]

Exciting news! 🎉 We’re thrilled to share positive topline results from our Phase 3 VALIANT study in C3G and IC-MPGN, which are rare kidney diseases with no approved treatment: https://t.co/TE6Unb2CQN

[Apellis Pharma @ApellisPharma]

It's #RareDiseaseDay, the most unique day of the year! We're proud to champion the rare disease community today and every day, and bring awareness to the unique challenges that people living with rare diseases face.

Join us and #ShowYourStripes for the rare disease community!

[Apellis Pharma @ApellisPharma]

Henry Winkler’s father-in-law had #AMD. Now, he wants to make sure you know about an advanced form of the disease, #GeographicAtrophy (GA).

Learn more at https://t.co/cySN0AZVOd. #WeAreApellis

[Apellis Pharma @ApellisPharma]

#TeamApellis was honored to be a part of @_BrightFocus' 50th Anniversary Celebration last night to honor the fearless scientists making strides in the treatment of macular degeneration, glaucoma and Alzheimer’s. Cheers to 50 years of progress!🎉

#WeAreApellis #BoldResearchCan

[Apellis Pharma @ApellisPharma]

#PrideMonth is here! 🏳️‍🌈

This month and every month, we’re proud to fearlessly support the LGBTQ+ community. We look forward to honoring this month with events, webinars and celebrations to increase our understanding, cultivate connection and celebrate diversity.

[Apellis Pharma @ApellisPharma]

👋 from Ottawa!

#TeamApellis is proud to support the Canadian Council of the Blind Symposium during #VisionHealthMonth. Thank you @CCBNational!

[Apellis Pharma @ApellisPharma]

Our work at #Apellis starts by controlling complement at C3.

C3 controls effects that can drive disease, like cell removal, inflammation, cell death or dysregulation. By controlling it, we aim to deliver life-changing medicines across a range of serious diseases.

[Health Innovation Alliance @Health_Alliance]

On behalf of our Board of Directors and Government Affairs Committee, thank you, @GovAndyBeshear, for making the Kentucky Healthcare Workforce Investment Fund a reality!

[Apellis Pharma @ApellisPharma]

Attending #TIDESUSA?

We’re proud our Chief Research Officer Lukas Scheibler will be a keynote speaker. Lukas will be discussing how the power of targeting C3 can address some of the most challenging diseases that patients face. Join him Monday at 11 am PST.

[Apellis Pharma @ApellisPharma]

Henry Winkler has seen the struggles of vision loss due to age-related macular degeneration (AMD) firsthand with his own family. That’s why we are proud to partner with him to drive awareness of #GeographicAtrophy (GA), an advanced form of AMD.

[Apellis Pharma @ApellisPharma]

Get to know #GeographicAtrophy (GA).

Learn more about GA disease progression. #KnowGA

[Apellis Pharma @ApellisPharma]

Today at #ARVO2023, we shared two oral presentations on functional post hoc analyses from Phase 3 studies of our #GeographicAtrophy (GA) treatment.

Read the full release below.

[Apellis Pharma @ApellisPharma]

#RegulatoryUpdate: We’re happy to share the validation of four marketing applications for our #GeographicAtrophy (GA) treatment outside the U.S. 🌎

Approval decisions are expected in the first half of 2024.

[Apellis Pharma @ApellisPharma]

For those living with age-related macular degeneration (AMD), it could progress to a more advanced form called #GeographicAtrophy (GA).

Hear what Susie, a patient living with GA, has to say about early diagnosis.

[cedric francois @cgfran01]

@steen1969 @GustavosMexGril That can be arranged 😂

[Life Science Report @lifesciencerpt]

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign $APLS https://t.co/p7yo9LUh4I

[Apellis Pharma @ApellisPharma]

📢 Big news! Now introducing – the GA Won’t Wait™ campaign. We’ve teamed up with acclaimed actor Henry Winkler to raise awareness of #GeographicAtrophy (GA) and what to do if you are over 60 and notice changes in vision.

[Apellis Pharma @ApellisPharma]

Measuring functional vision loss for patients with #GeographicAtrophy (GA) is critical to understanding disease progression. Click below to watch Dr. Holekamp explain why and how she does this.

#GAKnowledge

[Apellis Pharma @ApellisPharma]

At our core, we at #TeamApellis are committed to improving lives. This means understanding how #GeographicAtrophy (GA) impacts patients and their families every day.

Real patient stories inform and inspire us to make a difference.